PWM
AGIO icon

Parkworth Wealth Management’s Agios Pharmaceuticals AGIO Stock Holding History

Parkworth Wealth Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$33 – 1230
2024
Q4 		$33 Buy
+1
New +$47 ﹤0.01% 1212

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Parkworth Wealth Management's AGIO Position: Q1 2025 in Review

Parkworth Wealth Management sold out of Agios Pharmaceuticals (AGIO) in Q1 2025, closing a stake of 1 share — an estimated $33 sold.

Parkworth Wealth Management first reported a position in AGIO in Q4 2024 and held it in 1 quarter. The position peaked at $33 in Q4 2024. 221 funds tracked by Wall St. Rank hold AGIO as of Q1 2025.

  • Parkworth Wealth Management reported no remaining Agios Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Parkworth Wealth Management sold 1 Agios Pharmaceuticals share in Q1 2025, an estimated $33.
  • Parkworth Wealth Management first reported a position in Agios Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Parkworth Wealth Management's Agios Pharmaceuticals position peaked at $33 in Q4 2024.
  • 221 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2025.

Based on Parkworth Wealth Management's 13F filing for Q1 2025, filed 5 May 2025.